Clinical outcomes of patients with giant cell arteritis treated with tocilizumab in real-world clinical practice: decreased incidence of new visual manifestations

BACKGROUND: Placebo-controlled clinical trials have demonstrated the efficacy of tocilizumab (TCZ) for remission maintenance and glucocorticoid sparing in patients with giant cell arteritis (GCA). However, limited data exist on the effectiveness and safety of TCZ for GCA in real-world clinical pract...

Descripción completa

Detalles Bibliográficos
Autores principales: Unizony, Sebastian, McCulley, Timothy J., Spiera, Robert, Pei, Jinglan, Sidiropoulos, Paris N., Best, Jennie H., Birchwood, Christine, Pavlov, Andrey, Stone, John H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7789742/
https://www.ncbi.nlm.nih.gov/pubmed/33407817
http://dx.doi.org/10.1186/s13075-020-02377-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7789742/
https://www.ncbi.nlm.nih.gov/pubmed/33407817
http://dx.doi.org/10.1186/s13075-020-02377-8

Ejemplares similares